MapLight Therapeutics (MPLT) 10% owner Catalyst4 bought 4,400,000 shares for $50.1M at $11.38
Insider transactions reported
Catalyst4, Inc. (10% owner at MapLight Therapeutics Inc., MPLT) reported that they bought 4,400,000 shares for $50.1M at $11.38 on Aug 14, 2026. After these transactions the filing shows 25,306,689 shares held indirectly (See footnote).
- Reporting person
- Catalyst4, Inc.
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Open-market purchase (P) | Voting Common Stock1 | +4,400,000 | $11.38 | $50.1M | 25,306,689 indirect |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Open-market purchase (P) | Warrants (right to buy)On 2,928,686 Voting Common Stock1, 2, 3 | +2,928,686 | $11.38 | $33.3M | 2,928,686 indirect |
Holdings before and after
- Voting Common Stock: 20,906,689 to 25,306,689 indirect, See footnote
- Warrants (right to buy): 0 to 2,928,686 indirect, See footnote
Footnotes from the filing
- 1. The shares are held of record by Catalyst4, Inc. ( Catalyst4 ). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.
- 2. The warrant is immediately exercisable, however, the warrant may not be exercised if the aggregate number of shares of voting common stock beneficially owned by the reporting person immediately following such exercise would exceed 49.99%.
- 3. The warrants will not expire until exercised in full.
Transaction codes in this filing
- Open-market purchase:
- Code P marks a purchase in the open market or a private deal. The insider paid for these securities.
FAQ
What did Catalyst4 report in this MPLT Form 4?
Catalyst4, Inc. (10% owner at MapLight Therapeutics Inc., MPLT) reported that they bought 4,400,000 shares for $50.1M at $11.38 on Aug 14, 2026. After these transactions the filing shows 25,306,689 shares held indirectly (See footnote).
How many MPLT shares does Catalyst4 hold after this filing?
The filing shows 25,306,689 shares held indirectly (See footnote) after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code P mean on an SEC Form 4?
Code P marks a purchase in the open market or a private deal. The insider paid for these securities.
Historical context for MPLT
Across the 26 sessions after earlier MPLT headlines, the stock closed higher 19 times and lower 7 times, with a median move of 3.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MPLT | SPY |
|---|---|---|---|
| Aug 14, 2026 | MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | +1.5% | -0.2% |
| Aug 13, 2026 | MapLight Therapeutics Announces $150 Million Private Placement Financing | +1.8% | +0.7% |
| Aug 10, 2026 | MapLight Therapeutics downgraded by UBS with a new price target | +0.1% | -0.0% |
| Jul 28, 2026 | MapLight Therapeutics downgraded by Morgan Stanley with a new price target | +24.3% | +0.2% |
| Jul 27, 2026 | MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia | -72.9% | +0.0% |
| Jul 21, 2026 | BMO Capital Markets initiated coverage on MapLight Therapeutics with a new price target | +4.0% | +0.8% |
Earlier insider filings at MPLT
- Aug 5, 2026Chief Scientific Officer Lillie James Woodruff sold $276,908 worth of Voting Common Stock (22,082 units at $12.54) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 202,380 units (SEC Form 4)
- Jul 30, 2026Large owner Catalyst4, Inc. bought $15,314,794 worth of Voting Common Stock (1,209,225 units at $12.66) (SEC Form 4)
- Jul 29, 2026Director Cox Troy bought $148,702 worth of Voting Common Stock (15,620 units at $9.52) (SEC Form 4)
- Jul 20, 2026Chief Discovery Officer Kreitzer Anatol sold $1,345,894 worth of Voting Common Stock (36,284 units at $37.09) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 174,906 units (SEC Form 4) to cover withholding tax
- Jul 20, 2026CAO and Interim CFO Gillis Jonathan sold $1,372,668 worth of Voting Common Stock (36,979 units at $37.12) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 144,240 units (SEC Form 4) to satisfy tax liability
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2025
Follow MPLT and get a push notification the moment its next story breaks.